GW501516

GW501516, commonly known as Cardarine, was initially developed for the treatment of obesity, diabetes, and cardiovascular issues. It was later found to be effective in reducing negative cholesterol, the type that contributes to arterial blockage. In clinical trials involving a dosage of 10 mg of Cardarine, HDL (the "good" cholesterol) increased by 16.9% after several months of use.

In studies, mice subjected to exhaustive running trials demonstrated improved performance while administered GW501516.

Cancer Risk Claim: At the recommended dosage for large animals, there is no associated cancer risk. A common misconception is that GW501516 may induce cancer; however, this stems from rodent studies in which specific breeds of rats, known to be prone to cancer, were given 100 times the recommended dose per body weight daily. The development of cancer in these cases would likely have occurred regardless of the compound's presence, and it is never advisable to administer any substance at such an excessive dosage.

 This is a 30 count bag of capsules, dosed at 10mg per capsule.